Top Small Cap Stocks To Keep An Eye On - October 16th

Key Points

• MarketBeat’s screener identified seven small-cap stocks with unusually high recent dollar trading volume: D. Boral ARC Acquisition I, AltC Acquisition, Inflection Point Acquisition Corp. II, Spring Valley Acquisition, Inflection Point Acquisition, Bitfarms, and Recursion Pharmaceuticals.
• Five of the highlighted companies are blank-check or special-purpose acquisition companies (SPACs) seeking business combinations, including XLAB, ALCC, IPXX, SV, and IPAX.
• Bitfarms operates cryptocurrency-mining facilities focused on Bitcoin, while Recursion Pharmaceuticals is developing several drug candidates in clinical trials. Small-cap stocks can offer growth potential but generally involve higher volatility, lower liquidity, and greater economic sensitivity.

D. Boral ARC Acquisition I, AltC Acquisition, Inflection Point Acquisition Corp. II, Spring Valley Acquisition, Inflection Point Acquisition, Bitfarms, and Recursion Pharmaceuticals are the seven Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of companies with relatively small market capitalizations, typically ranking below large- and mid-cap companies by total market value. They may offer greater growth potential but generally carry higher volatility and risk, including lower liquidity and greater sensitivity to economic conditions. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

D. Boral ARC Acquisition I (XLAB)

We are a blank check company incorporated on March 20, 2025 as a BVI business company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination.

Read Our Latest Research Report on XLAB

AltC Acquisition (ALCC)

AltC Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was formerly known as Churchill Capital Corp VIII and changed its name to AltC Acquisition Corp.

Read Our Latest Research Report on ALCC

Inflection Point Acquisition Corp. II (IPXX)

Read Our Latest Research Report on IPXX

Spring Valley Acquisition (SV)

Read Our Latest Research Report on SV

Inflection Point Acquisition (IPAX)

Read Our Latest Research Report on IPAX

Bitfarms (BITF)

Bitfarms Ltd. engages in the mining of cryptocurrency coins and tokens in Canada, the United States, Paraguay, and Argentina. It owns and operates server farms that primarily validates transactions on the Bitcoin Blockchain and earning cryptocurrency from block rewards and transaction fees. The company also provides electrician services to commercial and residential customers in Quebec, Canada.

Read Our Latest Research Report on BITF

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Read Our Latest Research Report on RXRX

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.